DUBLIN, Jan. 7, 2021 /PRNewswire/ -- The "Global Markets and Technologies for Advanced Drug Delivery Systems" report has been added to ResearchAndMarkets.com's offering.
This report represents a current and important business tool to evaluate technologies, trends, products, and market participants in the advanced drug delivery sector. The geographic scope of this study covers the U.S. and companies worldwide. The report identifies the main elements of advanced drug delivery products and trends in different types of industries.
62 data tables 62 additional tables
An overview of the global markets and technologies for advanced drug delivery systems
Analyses of global market trends, with data from 2018, 2019, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2025
A look into the current state, setbacks, innovations, and future trends, and coverage of clinical trials in drug delivery systems
Discussion on the different categories of drug delivery, and details of acquisitions, mergers, and alliances by companies and global organizations
Description of advanced immediate-release technology and delayed-release and pulsatile release drug delivery technology
Information on monoclonal antibodies (MAbs), Prodrugs, and other drug carriers of advanced drug delivery systems
Insights of the regulatory environment, and the technology involved, including the latest trends and developments
Company profiles of major players including Alcon, Bausch & Lomb, Baxter International Inc., Eisai Co. Ltd., GlaxoSmithKline PLC, Eli Lilly, Novartis, and Sanofi
Drug delivery refers to technologies, formulations based on drug vehicles or carriers, and approaches (routes of administration) used to deliver drugs for various applications or therapeutic use.
Advanced drug delivery systems (ADDS) refer to the technologies used for controlling the rate of drug release. The type of technology used greatly depends on the type of disease, type of drug, and desired effect.
Advanced formulations and the use of novel drug vehicles have proven to increase the efficiency and efficacy of drug delivery systems, resulting in better treatment outcomes. Moreover, ADDS have become the holy grail in the treatment of several diseases and in unlocking the potential and value of pharma's existing compounds, as well as in exploring the potential of several new compounds, including ones that don't make it to market due to their limitations or issues related to factors such as adsorption, solubility, toxicity, molecular weight, metabolism, distribution, and excretion.
Although the quest for advanced drug delivery systems and formulations began long ago, ADDS have gained more momentum in the past few decades with the development and advancement of formulations and technologies such as modified-release technologies, targeted-release technologies, and formulations based on nanoparticles, microparticles, polymer conjugates, interfering RNA (siRNA), monoclonal antibodies, intelligent/smart polymers, osmotically modulated drug delivery, liposomes, and dendrimers.
Advanced drug delivery is an attractive industry with multifaceted growth opportunities in research and development, technologies, applications, and formulations.
Market analysis based on drug release mechanism shows that controlled-release and targeted-release formulations command the largest share of the market, and this is anticipated to remain the same over the next five years. Market analysis by route of administration clearly suggests that oral route administration and oral dosage forms dominate the market. The injectable sector is also expanding. To stay competitive, product differentiation is critical and demands high priority.
Oncology is the largest application area in the advanced drug delivery market due to the increasing use of new drug carriers and materials in targeted-release and controlled-release drug delivery, which has led to better drug formulations meeting unmet market needs. The COVID-19 pandemic is also fueling new developments in the respiratory sector.
Key Topics Covered:
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources and Methodology
Chapter 2 Summary and Highlights
Chapter 3 Evaluation of the Market Based on Technology
Overview of Advanced Drug Delivery Systems and Technologies
Modified Drug Delivery Segment
Summary of the Market for Advanced Drug Delivery Systems Based on Drug Release Mechanism
Chapter 4 Evaluation of the Market Based on Route of Administration
Overview of Advanced Drug Delivery Systems and Route of Administration
Oral Drug Delivery System Segment
Parenteral/Injectable Drug Delivery System Segment
Topical Drug Delivery System Segment
Transdermal Drug Delivery System Segment
Transmucosal Drug Delivery System Segment
Nasal and Pulmonary Drug Delivery System Segment
Ocular Drug Delivery System Segment
Oral-Buccal Drug Delivery Segment
Vaginal Drug Delivery Segment
Rectal Drug Delivery Segment
Transmucosal Drug Delivery System Segment
Implant Drug Delivery System Segment
Contraceptive Drug Delivery Device Segment
Summary of the Market for Advanced Drug Delivery Systems Based on Route of Administration
Chapter 5 Evaluation of the Market Based on Vehicle/Carrier
Overview of Advanced Drug Delivery Systems and Vehicles/Carriers
Liposomes as Drug Delivery Vehicles
Polymeric Therapeutics in Drug Delivery
Polymeric Micelles (Micelles) in Drug Delivery
Dendrimers in Drug Delivery
Polymers (Polymeric) in Drug Delivery
Nanocarriers/Nanoparticles in Drug Delivery
Microparticles/Microspheres in Drug Delivery
Monoclonal Antibodies (MAbs)
Other Drug Carriers
Summary of the Market for Advanced Drug Delivery Systems Based on Drug Delivery Vehicle/Carrier
Chapter 6 Evaluation of the Market Based on Application
Overview of Advanced Drug Delivery Systems and Applications
Gastrointestinal (GI) Disorders
Central Nervous System
Inflammatory Diseases and Allergies
Viral and Bacterial Diseases
Hormone Replacement Therapy and Gynecology
Other Therapeutic Applications
Summary of the Market for Advanced Drug Delivery Systems Based on Application
Chapter 7 Evaluation of the Market Based on Geographic Region
Overview of the Geographical Distribution of the Market for Advanced Drug Delivery Systems
Rest of the World (ROW)
Summary of the Market for Advanced Drug Delivery Systems by Region
Chapter 8 Overview of the Advanced Medical Device Industry
Mergers and Acquisitions (M&A)
Trends in Clinical Trials on Drug Delivery Systems
Chapter 9 Review of Patents on Advanced Drug Delivery Systems
Chapter 10 Market Summary
Overview of the Market for Advanced Drug Delivery Systems
Market Drivers and Restraints
Market Estimates and Analysis
Chapter 11 Company Profiles
Bausch & Lomb
Baxter International Inc.
Bayer Healthcare Pharmaceuticals
Eisai Co., Ltd.
Genentech Inc (Roche)
Generex Biotechnology Corp.
Gilead Sciences Inc.
Hisamitsu Pharmaceutical Co. Inc.
Eli Lilly And Co.
Janssen Biotech Inc.
Johnson & Johnson
Merck & Co.
Mylan Laboratories Inc.
Roche Holding Ag
Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/76i9pv
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/worldwide-industry-for-advanced-drug-delivery-systems-to-2025---featuring-alcon-baxter-international-and-novartis-among-others-301202687.html
SOURCE Research and Markets